nodes	percent_of_prediction	percent_of_DWPC	metapath
Droxidopa—DDC—nerve—acquired immunodeficiency syndrome	0.0282	0.103	CbGeAlD
Droxidopa—DDC—blood plasma—acquired immunodeficiency syndrome	0.0213	0.0776	CbGeAlD
Droxidopa—Blood pressure increased—Nevirapine—acquired immunodeficiency syndrome	0.0164	0.046	CcSEcCtD
Droxidopa—PAH—blood—acquired immunodeficiency syndrome	0.0137	0.0498	CbGeAlD
Droxidopa—SLC6A2—nerve—acquired immunodeficiency syndrome	0.0134	0.0489	CbGeAlD
Droxidopa—PAH—nervous system—acquired immunodeficiency syndrome	0.0111	0.0405	CbGeAlD
Droxidopa—Cardiac failure congestive—Zidovudine—acquired immunodeficiency syndrome	0.011	0.0309	CcSEcCtD
Droxidopa—PAH—central nervous system—acquired immunodeficiency syndrome	0.0107	0.0389	CbGeAlD
Droxidopa—Cardiac failure congestive—Efavirenz—acquired immunodeficiency syndrome	0.00967	0.0272	CcSEcCtD
Droxidopa—Urinary tract infection—Stavudine—acquired immunodeficiency syndrome	0.0086	0.0242	CcSEcCtD
Droxidopa—PAH—brain—acquired immunodeficiency syndrome	0.0085	0.0309	CbGeAlD
Droxidopa—ADRA2A—blood plasma—acquired immunodeficiency syndrome	0.00718	0.0261	CbGeAlD
Droxidopa—Urinary tract infection—Indinavir—acquired immunodeficiency syndrome	0.00695	0.0195	CcSEcCtD
Droxidopa—DDC—lung—acquired immunodeficiency syndrome	0.00685	0.0249	CbGeAlD
Droxidopa—DDC—nervous system—acquired immunodeficiency syndrome	0.00634	0.0231	CbGeAlD
Droxidopa—Urinary tract infection—Delavirdine—acquired immunodeficiency syndrome	0.00628	0.0177	CcSEcCtD
Droxidopa—DDC—central nervous system—acquired immunodeficiency syndrome	0.0061	0.0222	CbGeAlD
Droxidopa—Urinary tract infection—Ritonavir—acquired immunodeficiency syndrome	0.00581	0.0163	CcSEcCtD
Droxidopa—SLC16A10—lymphoid tissue—acquired immunodeficiency syndrome	0.00569	0.0207	CbGeAlD
Droxidopa—Urinary tract infection—Saquinavir—acquired immunodeficiency syndrome	0.00559	0.0157	CcSEcCtD
Droxidopa—Arrhythmia—Efavirenz—acquired immunodeficiency syndrome	0.00542	0.0152	CcSEcCtD
Droxidopa—Syncope—Zidovudine—acquired immunodeficiency syndrome	0.00539	0.0151	CcSEcCtD
Droxidopa—SLC16A10—blood—acquired immunodeficiency syndrome	0.00536	0.0195	CbGeAlD
Droxidopa—Loss of consciousness—Zidovudine—acquired immunodeficiency syndrome	0.00528	0.0148	CcSEcCtD
Droxidopa—Syncope—Indinavir—acquired immunodeficiency syndrome	0.00501	0.0141	CcSEcCtD
Droxidopa—ADRA1B—nervous system—acquired immunodeficiency syndrome	0.005	0.0182	CbGeAlD
Droxidopa—SLC16A10—vagina—acquired immunodeficiency syndrome	0.00496	0.0181	CbGeAlD
Droxidopa—Confusional state—Zidovudine—acquired immunodeficiency syndrome	0.00495	0.0139	CcSEcCtD
Droxidopa—Loss of consciousness—Indinavir—acquired immunodeficiency syndrome	0.00491	0.0138	CcSEcCtD
Droxidopa—ADRA1D—nervous system—acquired immunodeficiency syndrome	0.00489	0.0178	CbGeAlD
Droxidopa—DDC—brain—acquired immunodeficiency syndrome	0.00485	0.0176	CbGeAlD
Droxidopa—Shock—Zidovudine—acquired immunodeficiency syndrome	0.00483	0.0136	CcSEcCtD
Droxidopa—Feeling abnormal—Nevirapine—acquired immunodeficiency syndrome	0.00482	0.0135	CcSEcCtD
Droxidopa—ADRA1B—central nervous system—acquired immunodeficiency syndrome	0.00481	0.0175	CbGeAlD
Droxidopa—Syncope—Efavirenz—acquired immunodeficiency syndrome	0.00474	0.0133	CcSEcCtD
Droxidopa—ADRA1D—central nervous system—acquired immunodeficiency syndrome	0.00471	0.0171	CbGeAlD
Droxidopa—SLC16A10—lung—acquired immunodeficiency syndrome	0.0047	0.0171	CbGeAlD
Droxidopa—DDC—lymph node—acquired immunodeficiency syndrome	0.00468	0.017	CbGeAlD
Droxidopa—Feeling abnormal—Nelfinavir—acquired immunodeficiency syndrome	0.00466	0.0131	CcSEcCtD
Droxidopa—Loss of consciousness—Efavirenz—acquired immunodeficiency syndrome	0.00464	0.013	CcSEcCtD
Droxidopa—Feeling abnormal—Abacavir—acquired immunodeficiency syndrome	0.00458	0.0129	CcSEcCtD
Droxidopa—Hypertension—Efavirenz—acquired immunodeficiency syndrome	0.00456	0.0128	CcSEcCtD
Droxidopa—Syncope—Delavirdine—acquired immunodeficiency syndrome	0.00453	0.0127	CcSEcCtD
Droxidopa—Shock—Indinavir—acquired immunodeficiency syndrome	0.00449	0.0126	CcSEcCtD
Droxidopa—Headache—Amprenavir—acquired immunodeficiency syndrome	0.00447	0.0125	CcSEcCtD
Droxidopa—Loss of consciousness—Delavirdine—acquired immunodeficiency syndrome	0.00444	0.0125	CcSEcCtD
Droxidopa—Hypertension—Delavirdine—acquired immunodeficiency syndrome	0.00436	0.0123	CcSEcCtD
Droxidopa—Confusional state—Efavirenz—acquired immunodeficiency syndrome	0.00435	0.0122	CcSEcCtD
Droxidopa—Shock—Efavirenz—acquired immunodeficiency syndrome	0.00424	0.0119	CcSEcCtD
Droxidopa—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.00424	0.0119	CcSEcCtD
Droxidopa—Syncope—Ritonavir—acquired immunodeficiency syndrome	0.00419	0.0118	CcSEcCtD
Droxidopa—Confusional state—Delavirdine—acquired immunodeficiency syndrome	0.00416	0.0117	CcSEcCtD
Droxidopa—Loss of consciousness—Ritonavir—acquired immunodeficiency syndrome	0.00411	0.0115	CcSEcCtD
Droxidopa—Headache—Didanosine—acquired immunodeficiency syndrome	0.00407	0.0114	CcSEcCtD
Droxidopa—Shock—Delavirdine—acquired immunodeficiency syndrome	0.00406	0.0114	CcSEcCtD
Droxidopa—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	0.00404	0.0114	CcSEcCtD
Droxidopa—Hypertension—Ritonavir—acquired immunodeficiency syndrome	0.00403	0.0113	CcSEcCtD
Droxidopa—Syncope—Saquinavir—acquired immunodeficiency syndrome	0.00403	0.0113	CcSEcCtD
Droxidopa—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.00395	0.0111	CcSEcCtD
Droxidopa—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.00388	0.0109	CcSEcCtD
Droxidopa—Nausea—Didanosine—acquired immunodeficiency syndrome	0.00386	0.0108	CcSEcCtD
Droxidopa—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.00385	0.0108	CcSEcCtD
Droxidopa—Confusional state—Ritonavir—acquired immunodeficiency syndrome	0.00385	0.0108	CcSEcCtD
Droxidopa—ADRB1—lung—acquired immunodeficiency syndrome	0.00383	0.014	CbGeAlD
Droxidopa—ADRA1B—brain—acquired immunodeficiency syndrome	0.00382	0.0139	CbGeAlD
Droxidopa—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.00377	0.0106	CcSEcCtD
Droxidopa—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.00376	0.0106	CcSEcCtD
Droxidopa—Shock—Ritonavir—acquired immunodeficiency syndrome	0.00375	0.0105	CcSEcCtD
Droxidopa—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.00374	0.0105	CcSEcCtD
Droxidopa—ADRA1D—brain—acquired immunodeficiency syndrome	0.00374	0.0136	CbGeAlD
Droxidopa—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.00373	0.0105	CcSEcCtD
Droxidopa—Confusional state—Saquinavir—acquired immunodeficiency syndrome	0.0037	0.0104	CcSEcCtD
Droxidopa—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.00368	0.0103	CcSEcCtD
Droxidopa—ADRA1A—lymphoid tissue—acquired immunodeficiency syndrome	0.00368	0.0134	CbGeAlD
Droxidopa—Headache—Nevirapine—acquired immunodeficiency syndrome	0.00366	0.0103	CcSEcCtD
Droxidopa—Shock—Saquinavir—acquired immunodeficiency syndrome	0.00361	0.0101	CcSEcCtD
Droxidopa—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.00355	0.00997	CcSEcCtD
Droxidopa—ADRB1—nervous system—acquired immunodeficiency syndrome	0.00355	0.0129	CbGeAlD
Droxidopa—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.00355	0.00996	CcSEcCtD
Droxidopa—Headache—Stavudine—acquired immunodeficiency syndrome	0.00354	0.00993	CcSEcCtD
Droxidopa—Confusional state—Lamivudine—acquired immunodeficiency syndrome	0.00353	0.00992	CcSEcCtD
Droxidopa—Headache—Abacavir—acquired immunodeficiency syndrome	0.00348	0.00978	CcSEcCtD
Droxidopa—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.00347	0.00975	CcSEcCtD
Droxidopa—ADRA1A—blood—acquired immunodeficiency syndrome	0.00346	0.0126	CbGeAlD
Droxidopa—Shock—Lamivudine—acquired immunodeficiency syndrome	0.00344	0.00967	CcSEcCtD
Droxidopa—ADRB1—central nervous system—acquired immunodeficiency syndrome	0.00342	0.0124	CbGeAlD
Droxidopa—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.0034	0.00954	CcSEcCtD
Droxidopa—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.00336	0.00944	CcSEcCtD
Droxidopa—Nausea—Stavudine—acquired immunodeficiency syndrome	0.00335	0.00941	CcSEcCtD
Droxidopa—Nausea—Abacavir—acquired immunodeficiency syndrome	0.0033	0.00927	CcSEcCtD
Droxidopa—ADRA2C—blood—acquired immunodeficiency syndrome	0.0033	0.012	CbGeAlD
Droxidopa—SLC6A2—lung—acquired immunodeficiency syndrome	0.00326	0.0119	CbGeAlD
Droxidopa—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.00324	0.00911	CcSEcCtD
Droxidopa—SLC16A10—lymph node—acquired immunodeficiency syndrome	0.00321	0.0117	CbGeAlD
Droxidopa—ADRA2C—spinal cord—acquired immunodeficiency syndrome	0.00318	0.0116	CbGeAlD
Droxidopa—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	0.00314	0.00883	CcSEcCtD
Droxidopa—Headache—Zidovudine—acquired immunodeficiency syndrome	0.00307	0.00863	CcSEcCtD
Droxidopa—ADRA2C—vagina—acquired immunodeficiency syndrome	0.00305	0.0111	CbGeAlD
Droxidopa—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	0.00302	0.00849	CcSEcCtD
Droxidopa—SLC6A2—nervous system—acquired immunodeficiency syndrome	0.00302	0.011	CbGeAlD
Droxidopa—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.00302	0.00847	CcSEcCtD
Droxidopa—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.00291	0.00818	CcSEcCtD
Droxidopa—SLC6A2—central nervous system—acquired immunodeficiency syndrome	0.00291	0.0106	CbGeAlD
Droxidopa—ADRA2C—lung—acquired immunodeficiency syndrome	0.00289	0.0105	CbGeAlD
Droxidopa—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	0.00289	0.0081	CcSEcCtD
Droxidopa—Headache—Indinavir—acquired immunodeficiency syndrome	0.00286	0.00803	CcSEcCtD
Droxidopa—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.00285	0.008	CcSEcCtD
Droxidopa—ADRA1A—nervous system—acquired immunodeficiency syndrome	0.00281	0.0102	CbGeAlD
Droxidopa—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.00273	0.00766	CcSEcCtD
Droxidopa—ADRB1—brain—acquired immunodeficiency syndrome	0.00271	0.00988	CbGeAlD
Droxidopa—Nausea—Indinavir—acquired immunodeficiency syndrome	0.00271	0.00761	CcSEcCtD
Droxidopa—ADRA1A—central nervous system—acquired immunodeficiency syndrome	0.0027	0.00984	CbGeAlD
Droxidopa—Headache—Efavirenz—acquired immunodeficiency syndrome	0.0027	0.00758	CcSEcCtD
Droxidopa—ADRA2C—nervous system—acquired immunodeficiency syndrome	0.00268	0.00973	CbGeAlD
Droxidopa—ADRA2A—blood—acquired immunodeficiency syndrome	0.00263	0.00957	CbGeAlD
Droxidopa—Headache—Delavirdine—acquired immunodeficiency syndrome	0.00258	0.00726	CcSEcCtD
Droxidopa—ADRA2C—central nervous system—acquired immunodeficiency syndrome	0.00258	0.00937	CbGeAlD
Droxidopa—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.00256	0.00719	CcSEcCtD
Droxidopa—ADRA2A—spinal cord—acquired immunodeficiency syndrome	0.00253	0.00922	CbGeAlD
Droxidopa—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.00252	0.00708	CcSEcCtD
Droxidopa—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.00245	0.00688	CcSEcCtD
Droxidopa—ADRA2A—vagina—acquired immunodeficiency syndrome	0.00244	0.00887	CbGeAlD
Droxidopa—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.00243	0.00682	CcSEcCtD
Droxidopa—Headache—Ritonavir—acquired immunodeficiency syndrome	0.00239	0.00671	CcSEcCtD
Droxidopa—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.00232	0.0065	CcSEcCtD
Droxidopa—SLC6A2—brain—acquired immunodeficiency syndrome	0.00231	0.0084	CbGeAlD
Droxidopa—ADRA2A—lung—acquired immunodeficiency syndrome	0.00231	0.00839	CbGeAlD
Droxidopa—Headache—Saquinavir—acquired immunodeficiency syndrome	0.0023	0.00646	CcSEcCtD
Droxidopa—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.00227	0.00636	CcSEcCtD
Droxidopa—SLC6A2—lymph node—acquired immunodeficiency syndrome	0.00223	0.00812	CbGeAlD
Droxidopa—Headache—Lamivudine—acquired immunodeficiency syndrome	0.00219	0.00616	CcSEcCtD
Droxidopa—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.00218	0.00612	CcSEcCtD
Droxidopa—ADRA1A—brain—acquired immunodeficiency syndrome	0.00215	0.00781	CbGeAlD
Droxidopa—ADRA2A—nervous system—acquired immunodeficiency syndrome	0.00213	0.00777	CbGeAlD
Droxidopa—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.00208	0.00584	CcSEcCtD
Droxidopa—ADRA2A—central nervous system—acquired immunodeficiency syndrome	0.00206	0.00748	CbGeAlD
Droxidopa—ADRA2C—brain—acquired immunodeficiency syndrome	0.00204	0.00744	CbGeAlD
Droxidopa—ADRA2C—lymph node—acquired immunodeficiency syndrome	0.00198	0.00719	CbGeAlD
Droxidopa—ADRA2A—brain—acquired immunodeficiency syndrome	0.00163	0.00594	CbGeAlD
Droxidopa—ADRA2A—lymph node—acquired immunodeficiency syndrome	0.00158	0.00574	CbGeAlD
Droxidopa—ADRB1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000279	0.000757	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000279	0.000756	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000278	0.000754	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000278	0.000753	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000277	0.00075	CbGpPWpGaD
Droxidopa—ADRB3—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000275	0.000746	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000274	0.000743	CbGpPWpGaD
Droxidopa—ADRB2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000273	0.00074	CbGpPWpGaD
Droxidopa—PAH—Metabolism—ALB—acquired immunodeficiency syndrome	0.000271	0.000734	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000268	0.000727	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000268	0.000727	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000266	0.000721	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000266	0.00072	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000266	0.00072	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000266	0.00072	CbGpPWpGaD
Droxidopa—ADRB1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000263	0.000712	CbGpPWpGaD
Droxidopa—ADRB1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000263	0.000712	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000262	0.000711	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000262	0.000711	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000262	0.000709	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000262	0.000709	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.00026	0.000705	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.00026	0.000705	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.00026	0.000703	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000259	0.0007	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000258	0.000698	CbGpPWpGaD
Droxidopa—ADRB2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000257	0.000696	CbGpPWpGaD
Droxidopa—ADRB2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000257	0.000696	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000255	0.000692	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000254	0.000689	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000254	0.000687	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000252	0.000684	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000251	0.000681	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000248	0.000673	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000248	0.000673	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000248	0.000672	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000244	0.000662	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000244	0.000662	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000243	0.000659	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000243	0.000659	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000243	0.000657	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.00024	0.000651	CbGpPWpGaD
Droxidopa—ADRA2A—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	0.00024	0.00065	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000239	0.000649	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000239	0.000648	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000239	0.000648	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000238	0.000646	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000238	0.000646	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000237	0.000643	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000237	0.000643	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000237	0.000643	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000236	0.00064	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000236	0.00064	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000235	0.000636	CbGpPWpGaD
Droxidopa—ADRA2A—Hemostasis—CSF2—acquired immunodeficiency syndrome	0.000234	0.000634	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000233	0.000632	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000233	0.000632	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000231	0.000626	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000227	0.000615	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000226	0.000612	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000224	0.000608	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000221	0.000599	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000221	0.000598	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000221	0.000598	CbGpPWpGaD
Droxidopa—ADRA1D—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000219	0.000594	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000217	0.000589	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000217	0.000589	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000217	0.000588	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000217	0.000588	CbGpPWpGaD
Droxidopa—ADRA1D—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000216	0.000585	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000212	0.000576	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000212	0.000576	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000211	0.000571	CbGpPWpGaD
Droxidopa—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	0.000211	0.00057	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.00021	0.000569	CbGpPWpGaD
Droxidopa—SLC6A2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	0.000207	0.000562	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000205	0.000556	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000202	0.000546	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000202	0.000546	CbGpPWpGaD
Droxidopa—ADRA2B—Hemostasis—ALB—acquired immunodeficiency syndrome	0.000201	0.000545	CbGpPWpGaD
Droxidopa—ADRB1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.0002	0.000541	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000199	0.000539	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000198	0.000536	CbGpPWpGaD
Droxidopa—ADRA1D—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000198	0.000535	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000197	0.000535	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000197	0.000535	CbGpPWpGaD
Droxidopa—ADRB1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000197	0.000533	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000196	0.000532	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000196	0.000531	CbGpPWpGaD
Droxidopa—ADRB2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000195	0.000529	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000195	0.000528	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000193	0.000523	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000193	0.000523	CbGpPWpGaD
Droxidopa—ADRB2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000193	0.000522	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000191	0.000517	CbGpPWpGaD
Droxidopa—ADRA2C—Hemostasis—ALB—acquired immunodeficiency syndrome	0.000188	0.000509	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000185	0.000501	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000182	0.000494	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000182	0.000493	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000182	0.000493	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000182	0.000493	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000181	0.000492	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000181	0.000489	CbGpPWpGaD
Droxidopa—ADRB1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.00018	0.000488	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.00018	0.000487	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000179	0.000486	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000179	0.000486	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000179	0.000486	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000179	0.000486	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000179	0.000484	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000178	0.000483	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000178	0.000482	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000177	0.000481	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000177	0.00048	CbGpPWpGaD
Droxidopa—ADRB2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000176	0.000477	CbGpPWpGaD
Droxidopa—DDC—Metabolism—ALB—acquired immunodeficiency syndrome	0.000175	0.000475	CbGpPWpGaD
Droxidopa—ADRB3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000175	0.000475	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000175	0.000474	CbGpPWpGaD
Droxidopa—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	0.000175	0.000473	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000168	0.000455	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000167	0.000451	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000166	0.000449	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000165	0.000448	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000165	0.000448	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000164	0.000446	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000164	0.000445	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000164	0.000444	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000163	0.000443	CbGpPWpGaD
Droxidopa—ADRA2B—Hemostasis—IL2—acquired immunodeficiency syndrome	0.000163	0.000442	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000163	0.000441	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000163	0.000441	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000162	0.000439	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000162	0.000439	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000162	0.000438	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.00016	0.000433	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000159	0.000431	CbGpPWpGaD
Droxidopa—ADRB3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000159	0.000431	CbGpPWpGaD
Droxidopa—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	0.000155	0.000421	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000155	0.000419	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000155	0.000419	CbGpPWpGaD
Droxidopa—PAH—Disease—IL6—acquired immunodeficiency syndrome	0.000154	0.000418	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000153	0.000415	CbGpPWpGaD
Droxidopa—ADRA2A—Hemostasis—ALB—acquired immunodeficiency syndrome	0.000153	0.000413	CbGpPWpGaD
Droxidopa—ADRA2C—Hemostasis—IL2—acquired immunodeficiency syndrome	0.000152	0.000413	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000151	0.00041	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000151	0.000409	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.00015	0.000407	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.00015	0.000406	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000149	0.000403	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000148	0.000402	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000148	0.000401	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000147	0.000398	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000147	0.000397	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000146	0.000395	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000145	0.000392	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000141	0.000382	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000141	0.000382	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.00014	0.000378	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.00014	0.000378	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000139	0.000376	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000138	0.000373	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000138	0.000373	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000136	0.00037	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000136	0.00037	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000135	0.000367	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000134	0.000364	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000134	0.000363	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000132	0.000358	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.00013	0.000353	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.00013	0.000353	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000128	0.000348	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000128	0.000348	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000125	0.000337	CbGpPWpGaD
Droxidopa—ADRA2A—Hemostasis—IL2—acquired immunodeficiency syndrome	0.000124	0.000335	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000123	0.000333	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000121	0.000328	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000118	0.000319	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000116	0.000314	CbGpPWpGaD
Droxidopa—ADRA1D—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000114	0.000309	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000114	0.000309	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000114	0.000309	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000113	0.000305	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000107	0.00029	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000106	0.000288	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000106	0.000287	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000106	0.000287	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000106	0.000287	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000106	0.000286	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000105	0.000284	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000105	0.000283	CbGpPWpGaD
Droxidopa—ADRB1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000104	0.000282	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000104	0.000281	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000103	0.00028	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000103	0.000279	CbGpPWpGaD
Droxidopa—ADRB2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000102	0.000276	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.92e-05	0.000269	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.77e-05	0.000265	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.76e-05	0.000265	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.66e-05	0.000262	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	9.63e-05	0.000261	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.62e-05	0.000261	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.57e-05	0.000259	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	9.47e-05	0.000257	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.45e-05	0.000256	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	9.44e-05	0.000256	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.4e-05	0.000255	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	9.36e-05	0.000254	CbGpPWpGaD
Droxidopa—ADRB3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	9.35e-05	0.000253	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	9.24e-05	0.00025	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.94e-05	0.000242	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.8e-05	0.000238	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	8.74e-05	0.000237	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.67e-05	0.000235	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	8.6e-05	0.000233	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	8.54e-05	0.000231	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	8.41e-05	0.000228	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.06e-05	0.000218	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.94e-05	0.000215	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	7.82e-05	0.000212	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.81e-05	0.000212	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.64e-05	0.000207	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—ALB—acquired immunodeficiency syndrome	7.62e-05	0.000206	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.26e-05	0.000197	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.1e-05	0.000192	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—ALB—acquired immunodeficiency syndrome	6.19e-05	0.000168	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.12e-05	0.000166	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.09e-05	0.000165	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.58e-05	0.000151	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.55e-05	0.00015	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.53e-05	0.00015	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.52e-05	0.00015	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.5e-05	0.000149	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.46e-05	0.000148	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.43e-05	0.000147	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.16e-05	0.00014	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.14e-05	0.000139	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.08e-05	0.000138	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.06e-05	0.000137	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.51e-05	0.000122	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.49e-05	0.000122	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.19e-05	0.000114	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.17e-05	0.000113	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.6e-05	9.75e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.28e-05	8.88e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.25e-05	8.8e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.21e-05	8.69e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.04e-05	8.22e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.99e-05	8.09e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.65e-05	7.19e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.47e-05	6.68e-05	CbGpPWpGaD
